Compare RGTI & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGTI | RYTM |
|---|---|---|
| Founded | 2013 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8B | 6.4B |
| IPO Year | N/A | 2017 |
| Metric | RGTI | RYTM |
|---|---|---|
| Price | $17.22 | $89.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 14 |
| Target Price | $33.50 | ★ $129.43 |
| AVG Volume (30 Days) | ★ 22.3M | 712.7K |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.34 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $58.38 |
| Revenue Next Year | $179.00 | $83.95 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.86 | $45.91 |
| 52 Week High | $58.15 | $122.20 |
| Indicator | RGTI | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 44.93 | 35.17 |
| Support Level | $14.17 | $83.98 |
| Resistance Level | $17.42 | $96.92 |
| Average True Range (ATR) | 1.21 | 5.65 |
| MACD | 0.44 | -0.86 |
| Stochastic Oscillator | 57.11 | 15.42 |
Rigetti Computing Inc is engaged in the business of full-stack quantum computing. The company offers full-stack quantum computing platform as a cloud service to a wide range of end-users, directly through its Rigetti QCS platform, and also through cloud service providers. Its proprietary quantum-classical infrastructure provides ultra-low latency integration with public and private clouds for high-performance practical quantum computing. The company has developed the industry's first multi-chip quantum processor for scalable quantum computing systems. Geographically, the company derives the majority of its revenue from the United States.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.